Thematic photoMartin FalbisonerCC BY-SA 3.0Resized, encoded as WebP; displayed with responsive cropping under the original licenceSEC EDGAR published this disclosure on 2026-08-18. Read the original document for its full text and supporting detail.
Open the original document at SEC EDGAR ↗accession0001470831-26-000835
acquired disposedD
codeF
direct or indirectD
form4
is derivativefalse
issuer nameBridgeBio Pharma, Inc.
labelShares withheld for tax
Source record & verificationDates, provenance and technical details
Context
links are based on the recorded entity typeRecorded payloadStructured source data
Recorded payload
JSON payload as stored after parsing{
"accession": "0001470831-26-000835",
"acquired_disposed": "D",
"code": "F",
"direct_or_indirect": "D",
"form": "4",
"is_derivative": false,
"issuer_name": "BridgeBio Pharma, Inc.",
"label": "Shares withheld for tax",
"person_name": "Apuli Maricel",
"price": 79.86,
"role": "Chief Accounting Officer",
"security": "Common Stock",
"shares": 4714,
"shares_owned_after": 122687,
"source_path": "edgar/data/2058197/0001470831-26-000835.txt",
"ticker": "BBIO",
"transaction_date": "2026-08-16",
"value": 376460.04
}Evidence-based analysis
facts, provenance and explicit model coverageDescriptive evidence from the stored source record; it is not advice, a forecast or a legal conclusion.